Literature DB >> 11475366

Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

V Ponjavic1, S Andréasson.   

Abstract

PURPOSE: To examine the retinal function with different electrophysiological methods in twelve Swedish patients on long-term treatment (2-10 years) with the anti-epileptic drug vigabatrin.
METHODS: Ophthalmological examination of twelve consecutive patients included testing of visual acuity, fundus inspection and fundus photography, kinetic perimetry, full-field ERG and multifocal ERG.
RESULTS: All patients had a visual acuity of 0.7 or better. Fundus inspection revealed no pathology except in one patient who had a pallor of the optic disc. All patients had a normal appearance of the macula. The result of kinetic perimetry was normal in five patients while seven patients had a concentric defect of the visual field. The 30 Hz flicker cone b-wave amplitude in the full-field ERG was abnormal in all of the seven patients with a visual field defect. None of the patients with normal visual fields had a reduction of the 30 Hz flicker cone b-wave amplitude. Six of the twelve patients had a reduced multifocal ERG response but without any correlation with visual field defect.
CONCLUSION: Long-term treatment with vigabatrin seems to selectively reduce retinal cone function. The visual field defects in patients taking vigabatrin correlate with pathology in the full-field ERG (reduction of the cone b-wave amplitude). The results from this study indicate that electroretinography can be used for monitoring patients taking vigabatrin in a more objective manner than with visual field testing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11475366     DOI: 10.1023/a:1017589301855

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  19 in total

1.  Phenotypes in three Swedish families with X-linked retinitis pigmentosa caused by different mutations in the RPGR gene.

Authors:  S Andréasson; V Ponjavic; M Abrahamson; B Ehinger; W Wu; R Fujita; M Buraczynska; A Swaroop
Journal:  Am J Ophthalmol       Date:  1997-07       Impact factor: 5.258

2.  Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.

Authors:  N R Miller; M A Johnson; S R Paul; C A Girkin; J D Perry; M Endres; G L Krauss
Journal:  Neurology       Date:  1999-12-10       Impact factor: 9.910

3.  The field topography of ERG components in man--I. The photopic luminance response.

Authors:  E E Sutter; D Tran
Journal:  Vision Res       Date:  1992-03       Impact factor: 1.886

4.  Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.

Authors:  K Ruether; T Pung; U Kellner; B Schmitz; C Hartmann; M Seeliger
Journal:  Arch Ophthalmol       Date:  1998-06

5.  Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions.

Authors:  E A Wilson; M J Brodie
Journal:  BMJ       Date:  1997-06-07

6.  Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing.

Authors:  N Blackwell; J Hayllar; G Kelly
Journal:  BMJ       Date:  1997-06-07

7.  Severe persistent visual field constriction associated with vigabatrin.

Authors:  T Eke; J F Talbot; M C Lawden
Journal:  BMJ       Date:  1997-01-18

8.  Visual field defects associated with vigabatrin therapy.

Authors:  M C Lawden; T Eke; C Degg; G F Harding; J M Wild
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

9.  Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

Authors:  H Daneshvar; L Racette; S G Coupland; P J Kertes; A Guberman; D Zackon
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

10.  Effects of long-term vigabatrin on somatosensory-evoked potentials in epileptic patients.

Authors:  C Liegeois-Chauvel; P Marquis; D Gisselbrecht; R Pantieri; D Beaumont; P Chauvel
Journal:  Epilepsia       Date:  1989       Impact factor: 5.864

View more
  16 in total

1.  Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.

Authors:  Ulrika Kjellström; Sten Kjellström; Anitha Bruun; Sten Andréasson; Vesna Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-01       Impact factor: 2.379

2.  The effect of GABA and the GABA-uptake-blocker NO-711 on the b-wave of the ERG and the responses of horizontal cells to light.

Authors:  Renate Hanitzsch; Lea Küppers; Andreas Flade
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

3.  (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a potent γ-aminobutyric acid aminotransferase inactivator for the treatment of cocaine addiction.

Authors:  Yue Pan; Madina R Gerasimov; Trine Kvist; Petrine Wellendorph; Karsten K Madsen; Elena Pera; Hyunbeom Lee; Arne Schousboe; Mary Chebib; Hans Bräuner-Osborne; Cheryl M Craft; Jonathan D Brodie; Wynne K Schiffer; Stephen L Dewey; Steven R Miller; Richard B Silverman
Journal:  J Med Chem       Date:  2011-12-30       Impact factor: 7.446

4.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

5.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

6.  Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients.

Authors:  Maria Dettoraki; Antonis Kattamis; Ioannis Ladas; Konstantinos Maragkos; Chryssanthi Koutsandrea; Klio Chatzistefanou; Konstantinos Laios; Dimitrios Brouzas; Marilita M Moschos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-30       Impact factor: 3.117

7.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

8.  Treatment of epilepsy: the GABA-transaminase inhibitor, vigabatrin, induces neuronal plasticity in the mouse retina.

Authors:  Qing-Ping Wang; Firas Jammoul; Agnès Duboc; Jie Gong; Manuel Simonutti; Elisabeth Dubus; Cheryl M Craft; Wen Ye; José A Sahel; Serge Picaud
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  Retinal defect in children with infantile spasms of varying etiologies: An observational study.

Authors:  Michelle T McFarlane; Tom Wright; Blathnaid McCoy; O Carter Snead; Carol A Westall
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.